The inhaled Steroid Treatment as Regular Therapy in early asthma (START) study: rationale and design.

[1]  P. O'Byrne,et al.  Design and analytic considerations in determining the cost-effectiveness of early intervention in asthma from a multinational clinical trial. , 2001, Controlled Clinical Trials.

[2]  S. Pedersen,et al.  Effect of long-term treatment with inhaled budesonide on adult height in children with asthma. , 2000, The New England journal of medicine.

[3]  Edersen,et al.  EFFECT OF LONG-TERM TREATMENT WITH INHALED BUDESONIDE ON ADULT HEIGHT IN CHILDREN WITH ASTHMA , 2000 .

[4]  G. Oldaéus,et al.  Efficacy of once‐daily versus twice‐daily administration of budesonide by Turbuhaler® in children with stable asthma , 1999, Pediatric pulmonology.

[5]  Pauwels,et al.  Airway wall remodelling: does it occur and what does it mean? , 1999, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

[6]  J. Kemp,et al.  Once-daily budesonide inhalation suspension for the treatment of persistent asthma in infants and young children. , 1999, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[7]  E. R. Mcfadden,et al.  Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma. , 1999, The Journal of allergy and clinical immunology.

[8]  I. Herjavecz,et al.  Efficacy of once- and twice-daily administration of budesonide via Turbuhaler as initial therapy in patients with mild persistent asthma. , 1999, Respiratory medicine.

[9]  B. Källén,et al.  Congenital malformations after the use of inhaled budesonide in early pregnancy. , 1999, Obstetrics and gynecology.

[10]  M. Welch,et al.  A multiple-dosing, placebo-controlled study of budesonide inhalation suspension given once or twice daily for treatment of persistent asthma in young children and infants. , 1999, Pediatrics.

[11]  P. O'Byrne,et al.  Measuring efficacy and safety of different inhaled corticosteroid preparations. , 1998, The Journal of allergy and clinical immunology.

[12]  K. Carlsen,et al.  Clinical efficacy of low-dose inhaled budesonide once or twice daily in children with mild asthma not previously treated with steroids. , 1998, The European respiratory journal.

[13]  J Vestbo,et al.  A 15-year follow-up study of ventilatory function in adults with asthma. , 1998, The New England journal of medicine.

[14]  S. Suissa,et al.  Association of inhaled corticosteroid use with cataract extraction in elderly patients. , 1998, JAMA.

[15]  S. Pedersen,et al.  Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. , 1998, The European respiratory journal.

[16]  J. P. Powell,et al.  Once-daily budesonide: 400 micrograms once daily is as effective as 200 micrograms twice daily in controlling childhood asthma. PETITE Research Group. , 1998, International journal of clinical practice.

[17]  J. FitzGerald,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. , 1998, The New England journal of medicine.

[18]  S. Pedersen,et al.  Bone mineral density in children with asthma receiving long-term treatment with inhaled budesonide. , 1998, American journal of respiratory and critical care medicine.

[19]  D. Postma,et al.  Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. , 1997, The New England journal of medicine.

[20]  R. Cumming,et al.  Use of inhaled corticosteroids and the risk of cataracts. , 1997, The New England journal of medicine.

[21]  D. Postma,et al.  Adult patients may outgrow their asthma: a 25-year follow-up study. , 1997, American journal of respiratory and critical care medicine.

[22]  P. O'Byrne,et al.  A comparison of the efficacy and safety of inhaled corticosteroids in asthma , 1997, Allergy.

[23]  A. Stewart.  AIRWAY WALL REMODELLING in ASTHMA , 1996 .

[24]  R. Pauwels,et al.  GLOBAL STRATEGY FOR ASTHMA MANAGEMENT AND PREVENTION , 1996 .

[25]  P. O'Byrne,et al.  Efficacy and Cost Benefit of Inhaled Corticosteroids in Patients Considered to Have Mild Asthma in Primary Care Practice , 1996 .

[26]  A Pietinalho,et al.  Effect of early vs late intervention with inhaled corticosteroids in asthma. , 1995, Chest.

[27]  L. Boulet,et al.  Airway responsiveness and bronchial-wall thickness in asthma with or without fixed airflow obstruction. , 1995, American journal of respiratory and critical care medicine.

[28]  G. Russell,et al.  Posterior subcapsular cataract and inhaled corticosteroid therapy. , 1995, Thorax.

[29]  T. Haahtela,et al.  Effects of reducing or discontinuing inhaled budesonide in patients with mild asthma. , 1994, The New England journal of medicine.

[30]  M. Hibbert,et al.  Outcome of childhood asthma in mid-adult life , 1994, BMJ.

[31]  S. Pedersen,et al.  Effects of long-term treatment with an inhaled corticosteroid on growth and pulmonary function in asthmatic children. , 1994, Respiratory medicine.

[32]  C. G. Langdon,et al.  Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma. , 1994, Respiratory medicine.

[33]  P. Enright,et al.  Physiologic measures: pulmonary function tests. Asthma outcome. , 1994, American journal of respiratory and critical care medicine.

[34]  W. V. van Aalderen,et al.  Risk factors for the persistence of respiratory symptoms in childhood asthma. , 1993, The American review of respiratory disease.

[35]  P. Paré,et al.  Small airways dimensions in asthma and in chronic obstructive pulmonary disease. , 1993, The American review of respiratory disease.

[36]  M. Cheang,et al.  Absence of posterior subcapsular cataracts in young patients treated with inhaled glucocorticoids , 1993, The Lancet.

[37]  A. Stewart,et al.  Airway wall remodelling in asthma: a novel target for the development of anti-asthma drugs. , 1993, Trends in pharmacological sciences.

[38]  T. Haahtela,et al.  Airway mucosal inflammation even in patients with newly diagnosed asthma. , 1993, The American review of respiratory disease.

[39]  D. Postma,et al.  A comparison of bronchodilator therapy with or without inhaled corticosteroid therapy for obstructive airways disease. Dutch Chronic Non-Specific Lung Disease Study Group. , 1992, The New England journal of medicine.

[40]  Alfred O. Berg,et al.  Clinical Guidelines And Primary Care Guidelines For The Diagnosis And Management Of Asthma , 2012 .

[41]  M. Hughes,et al.  Effects of 22 months of treatment with inhaled corticosteroids and/or beta-2-agonists on lung function, airway responsiveness, and symptoms in children with asthma. The Dutch Chronic Non-specific Lung Disease Study Group. , 1992, The American review of respiratory disease.

[42]  J. Paton,et al.  Measuring compliance with inhaled medication in asthma. , 1992, Archives of disease in childhood.

[43]  R. Zuwallack,et al.  A comparison of the effects of bid and qid dosing on compliance with inhaled flunisolide. , 1992, Chest.

[44]  T. Haahtela,et al.  Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. , 1991, The New England journal of medicine.

[45]  S. Durham,et al.  Identification of activated T lymphocytes and eosinophils in bronchial biopsies in stable atopic asthma. , 1990, The American review of respiratory disease.

[46]  E. Juniper,et al.  Effect of long-term treatment with an inhaled corticosteroid (budesonide) on airway hyperresponsiveness and clinical asthma in nonsteroid-dependent asthmatics. , 1990, The American review of respiratory disease.

[47]  R. Djukanović,et al.  Mucosal inflammation in asthma. , 1990, The American review of respiratory disease.

[48]  A. Woolcock,et al.  Rate of decline of lung function in subjects with asthma. , 1987, European journal of respiratory diseases.